5th Apr 2019 14:02
LONDON (Alliance News) - Indivior PLC on Friday said that its RECOVER study found that 75% of patients with opioid addiction were abstinent from illicit opioids use a year after receiving 12 monthly injections of the company's Sublocade.
In the observational study, the patients self-reported their abstinence, with the results later confirmed by urine drug screen.
Patients were given the option to continue using the drug following the trial or chose to continue another form of medication-assisted treatment.
"RECOVER is assessing real-world outcomes in patients for up to two years after they completed our clinical phase 3 Sublocade study," Chief Scientific Officer Christian Heidbreder said. "We have invested in this research to help answer questions about how medication-assisted treatment can help patients with opioid use disorder maintain recovery in their communities and live healthier lives."
Furthermore, an additional 18-month safety study among Sublocade-treated patients reported "no new safety issues".
Data from this second study also supported the efficacy of Sublocade and its impact on retaining patients with opioid use disorder in treatment.
The abstinence rate from illicit opioids for patients treated with the drug increased throughout the study from 36% to 53% at week one to 82% to 93% at 18 months.
Patients who received either six or 12 once-monthly doses also had a high probability, at least 73%, of remaining in treatment for another six months.
Indivior shares were trading 1.2% lower at 96.70 pence each.
Related Shares:
Indivior